Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies

Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies

Background and objectivesSince the results of previous observational studies on the relationship between metabolic dysfunction-associated steatotic liver disease (MASLD) and pancreatic cancer were still controversial and inconsistent, we performed a systematic evaluation and meta-analysis of cohort...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Yi Zhang, Ben-Gang Zhou, Ji-Dong Zhan, Bin-Bin Du
Formatua:	Artikulua
Hizkuntza:	English
Argitaratua:	Frontiers Media S.A. 2024-03-01
Saila:	Frontiers in Oncology
Gaiak:	non-alcoholic fatty liver disease metabolic dysfunction-associated steatotic liver disease pancreatic cancer cohort studies meta-analysis systematic review
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1366195/full

Antzeko izenburuak

Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021
nork: Gong Feng, et al.
Argitaratua: (2025-03-01)

Metabolic dysfunction-associated fatty liver disease/metabolic dysfunction-associated steatotic liver disease: general provisions
nork: O.E. Abaturov, et al.
Argitaratua: (2024-04-01)

Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies
nork: Jian-Feng Zhao, et al.
Argitaratua: (2024-07-01)

Steatotic Liver Disease: New Nomenclature and Its Localization in the Russian Federation
nork: K. L. Raikhelson, et al.
Argitaratua: (2024-05-01)

A new name for an old problem. Metabolic dysfunction-associated steatotic liver disease - review of literature
nork: Adrian Kruszewski, et al.
Argitaratua: (2024-07-01)

Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
nork: Katharina Staufer, et al.
Argitaratua: (2023-07-01)

Effectiveness of Pemafibrate Dose Escalation on Metabolic Dysfunction-Associated Steatotic Liver Disease Refractory to Standard Dose
nork: Satoshi Shinozaki, et al.
Argitaratua: (2025-02-01)

Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease
nork: Yu-Ming Cheng, et al.
Argitaratua: (2024-12-01)

The clinician's view on the advantages and contradictions of the new nomenclature of steatotic liver disease: A review
nork: Chavdar S. Pavlov, et al.
Argitaratua: (2024-05-01)

Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
nork: Yumin Wang, et al.
Argitaratua: (2024-01-01)

Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
nork: Haixiang Zheng, et al.
Argitaratua: (2024-09-01)

Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
nork: Tsubasa Tsutsumi, et al.
Argitaratua: (2024-04-01)

Mitochondrial Dysfunction-Associated Mechanisms in the Development of Chronic Liver Diseases
nork: Madan Kumar Arumugam, et al.
Argitaratua: (2023-10-01)

Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
nork: Jaehyun Bae, et al.
Argitaratua: (2024-11-01)

Association of plain water intake with risk of all-cause and cause-specific mortality in individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease
nork: Na Zhao, et al.
Argitaratua: (2024-10-01)

Risk of Hepatocellular Carcinoma by Steatotic Liver Disease and Its Newly Proposed Subclassification
nork: Byeong Geun Song, et al.
Argitaratua: (2024-03-01)

Exploring the epidemiology and awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among health sciences students in an academic health care institute in India
nork: Umasankari S., et al.
Argitaratua: (2024-12-01)

Metabolic dysfunction-associated steatotic liver disease
nork: Chieh Chen, et al.
Argitaratua: (2024-12-01)

Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study
nork: Yebei Liang, et al.
Argitaratua: (2025-02-01)

Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort studyResearch in context
nork: Joon Ho Moon, et al.
Argitaratua: (2023-11-01)

Complement 3a receptor 1 on macrophages and Kupffer cells is not required for the pathogenesis of metabolic dysfunction-associated steatotic liver disease
nork: Edwin A Homan, et al.
Argitaratua: (2025-01-01)

Deciphering the liver enigma: distinguishing drug-induced liver injury and metabolic dysfunction-associated steatotic liver disease—a comprehensive narrative review
nork: Miren García-Cortés, et al.
Argitaratua: (2023-12-01)

Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
nork: Myrsini Orfanidou, et al.
Argitaratua: (2024-12-01)

Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease
nork: In-gyu Park, et al.
Argitaratua: (2024-07-01)

Projected Healthcare System Cost Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in Canada
nork: K. Ally Memedovich, et al.
Argitaratua: (2024-01-01)

Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity
nork: Katharina L. Hupa-Breier, et al.
Argitaratua: (2025-03-01)

Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease
nork: Zehra N. Kocas-Kilicarslan, et al.
Argitaratua: (2024-01-01)

Impact of pemafibrate in patients with metabolic dysfunction‐associated steatotic liver disease complicated by dyslipidemia: A single‐arm prospective study
nork: Hiroki Ono, et al.
Argitaratua: (2024-04-01)

High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease
nork: Jingjing Hu, et al.
Argitaratua: (2024-08-01)

Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease
nork: Ahmed Mohamed ElGhandour, et al.
Argitaratua: (2024-11-01)

Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes
nork: Lushan Xiao, et al.
Argitaratua: (2024-07-01)

Hypothyroidism/subclinical hypothyroidism and metabolic dysfunction-associated steatotic liver disease: advances in mechanism and treatment
nork: Sicheng Pu, et al.
Argitaratua: (2025-02-01)

The impact of fasting on cardiovascular risk control in patients with metabolic dysfunction-associated steatotic liver disease
nork: Anna E. Płatek, et al.
Argitaratua: (2023-09-01)

The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis
nork: Yvonne Burmeister, et al.
Argitaratua: (2023-12-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
nork: Jessica M. Rubino, et al.
Argitaratua: (2025-01-01)

Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults
nork: Jaejun Lee, et al.
Argitaratua: (2025-01-01)

ASSOCIATION BETWEEN ANXIETY AND DEPRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
nork: Eloyse Cristina BOTACIN, et al.
Argitaratua: (2024-07-01)

FLI and FIB-4 in diagnosing metabolic dysfunction-associated steatotic liver disease in primary care: High prevalence and risk of significant disease
nork: Mário Reis Álvares-da-Silva, et al.
Argitaratua: (2025-01-01)

Predictors of Significant Fibrosis Among People Living with HIV with Metabolic Dysfunction- Associated Steatotic Liver Disease
nork: Thaninee Prasoppokakorn, et al.
Argitaratua: (2024-12-01)

Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease
nork: Facundo Maiorana, et al.
Argitaratua: (2024-11-01)